Stroke Management Market – Detailed industry report live covering players Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corporation, GE Healthcare, GlaxoSmithKline

Stroke is a medical condition in which blood clot blocks the blood vessels and interrupts the blood flow to the brain, resulting in cell death. Under the guidelines of American Stroke Association, there are of 3 types of strokes: ischemic stroke (an obstruction within blood vessel that delivers blood to the brain), hemorrhagic stroke (weakened blood vessel rapture due to high blood pressure), and transient ischemic attack (identified by temporary clot). Stroke can be caused due to medical conditions such as high blood pressure, diabetes, heart disease or life style habits such as smoking, physically inactive lifestyle, alcohol abuse, obesity, and various others. Moreover, uncontrollable factors such as increasing age, male sex, heredity, and ethnicity contribute to stroke. According to the World Health Organization (WHO), in 2015, stroke is the second leading global cause of death after heart disease and it accounted for 11.8% of total deaths worldwide.

Stroke management market is driven by advancements in technology and therapeutic along with increasing incidence of stroke and strict approval system is expected to hinder growth of global stroke management market.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1483

Global Stroke Management Market Taxonomy:

Diagnostics
Computed Tomography Scan (CT scan)
Echocardiography
Magnetic Resonance Imaging (MRI)
Carotid Ultrasound
Nuclear Medicine Imaging
Cerebral Angiography
Electrocardiography
Other Diagnostics

The advancements in technology and facilities to diagnose stroke and discovery of novel drugs will drive growth of stroke management market. Technologies such as robotic-assisted angiography or exoskeleton soft suit for rehabilitation are the upcoming future of stroke management market. Moreover, an idea of Mobile Stroke Treatment Units (MSTU) was introduced in Germany in 2003 and was used in Berlin for the first time in 2008. The Prehospital Acute Neurological Treatment and Optimization of Medical care in Stroke Study (PHANTOM-S) in Germany reported that their MSTU significantly decreased stroke alert-to-treatment times from 76 minutes to 52 minutes, and significantly increased thrombolysis rates from 21% to 33% with no increase in the risk of intracerebral hemorrhage. Therefore, advancements in mobile stroke treatment units is expected to fuel growth of stroke management market.

Conventional stroke treatment aims at minimizing damage caused due to acute stroke by intravenous thrombolytics and endovascular thrombectomy, however, there is no proven cure for reversing the damage. It calls for a robust armamentarium of therapies for stroke treatment such as cell therapy, which has immense potential to propel the market in near future. Cell therapy can be used for re-vascularization after stroke and for reduction of cerebral inflammation. Phase II clinical trials of intravenous transplantation of autologous bone-marrow stem cells have reported safety and tolerability in stroke patients. Other pending clinical trials such as PISCES can also be considered as future candidates for clinical practice. Sonothrombolysis is another approach, which uses low-frequency ultrasound waves to cause thrombosis. The prototype for sonothrombolysis device is been tested by North Carolina State University and has filed a patent on the technology. Under equipped or untrained emergency medical service provider and strict governmental regulations on the approval of new drugs or advanced devices are some of the factors that are likely to hinder growth of stroke management market.

The narrow range of drugs available for the treatment of stroke offers wide options for research organizations and key players to excel the stroke management market by discovering novel drugs with less side-effects. Merger and acquisition is the key strategy to expand the stroke management market. In May 2017, Codman Neuro, a part of Johnson & Johnson acquired Neuravi Ltd., an Irish medical device company that manufactures advance revascularization device and EmboTrap is a device manufactured by this company. The EmboTrap platform was intended to address the critical need for rapid restoration of blood flow in stroke patients and combination of Neuravi’s expertise in clot research with Codman Neuro’s global resources aims to accelerate development in the field of acute ischemic stroke treatment. Furthermore, strong therapeutic pipeline of players will enhance growth of stroke management market. In 2018, NuvOx Pharma’s dodecafluoropentane emulsion (DDFPe) IV entered phase II clinical trials and DDFPe aims to deliver oxygen to hypoxic tissue of brain. Also, in 2018, DiaMedica Therapeutics Inc. announced DM199, a recombinant human tissue kallikrein, to enter phase II clinical trial and it is expected to be a breakthrough in stroke treatment.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1483

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.